Geode Capital Management LLC Buys 94,870 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Geode Capital Management LLC boosted its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 7.1% in the third quarter, HoldingsChannel reports. The institutional investor owned 1,425,827 shares of the biopharmaceutical company’s stock after buying an additional 94,870 shares during the quarter. Geode Capital Management LLC’s holdings in Vanda Pharmaceuticals were worth $6,689,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of VNDA. Meeder Asset Management Inc. bought a new stake in shares of Vanda Pharmaceuticals in the 2nd quarter worth $39,000. ORG Wealth Partners LLC purchased a new position in Vanda Pharmaceuticals during the third quarter worth about $40,000. China Universal Asset Management Co. Ltd. grew its position in Vanda Pharmaceuticals by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 4,374 shares in the last quarter. XTX Topco Ltd bought a new stake in Vanda Pharmaceuticals in the 2nd quarter worth about $75,000. Finally, Intech Investment Management LLC purchased a new stake in Vanda Pharmaceuticals in the 3rd quarter valued at about $84,000. 88.14% of the stock is currently owned by institutional investors.

Insider Activity

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the business’s stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $5.17, for a total value of $25,850.00. Following the sale, the director now directly owns 44,857 shares in the company, valued at $231,910.69. The trade was a 10.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 8.90% of the company’s stock.

Wall Street Analysts Forecast Growth

VNDA has been the topic of a number of research analyst reports. StockNews.com assumed coverage on Vanda Pharmaceuticals in a research note on Saturday. They issued a “hold” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Vanda Pharmaceuticals in a research report on Monday, December 23rd.

Vanda Pharmaceuticals Stock Performance

NASDAQ VNDA opened at $4.85 on Friday. The company has a market capitalization of $282.79 million, a PE ratio of -17.32 and a beta of 0.77. Vanda Pharmaceuticals Inc. has a 52-week low of $3.46 and a 52-week high of $6.75. The company has a 50-day simple moving average of $4.88 and a 200 day simple moving average of $5.14.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.